A Pilot Study to Assess the Effect of Prucalopride on Cognitive Functioning in Patients with Schizophrenia - PruCog

St Johns National Academy Of Health Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•i)Diagnosed as schizophrenia by DSM 5 criteria
•ii)Age between 18 to 55 years
•iii)A minimum of one year of duration of illness
•iv)Clinically stable with a stable therapeutic dose of antipsychotics for at least 3 months prior to the recruitment
•v)Participants who can read and write English or Kannada

•i)Participants who are acutely symptomatic and are uncooperative for assessments
•ii)Co morbid with other psychiatric illness including mood disorders and substance use disorders except tobacco
•iii)Participants already diagnosed with Intellectual Disability Disorder, head injury
•iv)Participants administered MECT (modified electroconvulsive therapy) in the past 6 months
•v)Participants with uncorrected sensory impairments
•vi)Use of Donepezil, Rivastigmine, Memantine, Benzodiazepines
•vii)Participants already on prucalopride
•viii)Participants with contraindications to prucalopride like hypersensitivity or diagnosed with intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, gastrointestinal disorders like Ulcerative colitis, Crohn’s disease, Intestinal ulcers, toxic megacolon or megarectum
•ix)Use of concomitant herbal remedies, alternative medicines
•x)Women who are pregnant or lactating
•xi)Current history of suicidal ideation, intention or attempts as assessed during the clinical interview

发起方